Propanc Biopharma retires all Series A Preferred Stock; no shares outstanding

Propanc Biopharma, Inc.

Filed Certificate of Retirement with Delaware to eliminate Series A Preferred Stock from charter.
No shares of Series A Preferred Stock are currently outstanding.
Retired shares become authorized but unissued preferred stock without designation.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Propanc Biopharma, Inc.: Retired Series A Preferred Stock and amended Certificate of Incorporation to eliminate all references to the series (effective 2023-03-15).

Change: charter amendment
Effective: 2023-03-15

Exact text from the filing

On March 15, 2023, Propanc Biopharma, Inc. (the “Company”), filed a certificate with the Secretary of State of Delaware (the “Certificate of Retirement”), effecting the retirement and cancellation of the Company’s Series A Preferred Stock (the “Series A Preferred Stock”) to eliminate from its Certificate of Incorporation, as amended (the “Certificate of Incorporation”), all references to the Series A Preferred Stock, including, without limitation, the Certificate of Designation governing the Series A Preferred Stock.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-008082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.